456 related articles for article (PubMed ID: 25521481)
1. Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer.
Kachakova D; Mitkova A; Popov E; Popov I; Vlahova A; Dikov T; Christova S; Mitev V; Slavov C; Kaneva R
DNA Cell Biol; 2015 Mar; 34(3):189-200. PubMed ID: 25521481
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
[TBL] [Abstract][Full Text] [Related]
3. Increased Expression of miR-494 in Serum of Patients with Prostate Cancer and its Potential Diagnostic Value.
Cai B; Peng JH
Clin Lab; 2019 Aug; 65(8):. PubMed ID: 31414754
[TBL] [Abstract][Full Text] [Related]
4. Combining PHI and miRNAs as Biomarkers in Prostate Cancer Diagnosis and Prognosis.
Ibrahim NH; Abdellateif MS; Thabet G; Kassem SH; El-Salam MA; El-Leithy AA; Selim MM
Clin Lab; 2019 Jul; 65(7):. PubMed ID: 31307177
[TBL] [Abstract][Full Text] [Related]
5. MiR-139-5p is Increased in the Peripheral Blood of Patients with Prostate Cancer.
Pang C; Liu M; Fang W; Guo J; Zhang Z; Wu P; Zhang Y; Wang J
Cell Physiol Biochem; 2016; 39(3):1111-7. PubMed ID: 27562849
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Value of Circulating miR-324 for Prostate Cancer.
Jin YY; Tong SQ; Tong M
Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969074
[TBL] [Abstract][Full Text] [Related]
7. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
[TBL] [Abstract][Full Text] [Related]
8. Serum Levels of miR-223-3p and miR-223-5p in Prostate Diseases.
Dülgeroğlu Y; Eroğlu O
Microrna; 2020; 9(4):303-309. PubMed ID: 33155933
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine.
Fredsøe J; Rasmussen AKI; Thomsen AR; Mouritzen P; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Eur Urol Focus; 2018 Dec; 4(6):825-833. PubMed ID: 28753866
[TBL] [Abstract][Full Text] [Related]
10. The association of let-7c, miR-21, miR-145, miR-182, and miR-221 with clinicopathologic parameters of prostate cancer in patients diagnosed with low-risk disease.
Kurul NO; Ates F; Yilmaz I; Narli G; Yesildal C; Senkul T
Prostate; 2019 Jul; 79(10):1125-1132. PubMed ID: 31045265
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic significance of miR-21, miR-141, miR-18a and miR-221 as novel biomarkers in prostate cancer among Egyptian patients.
Ibrahim NH; Abdellateif MS; Kassem SH; Abd El Salam MA; El Gammal MM
Andrologia; 2019 Nov; 51(10):e13384. PubMed ID: 31483058
[TBL] [Abstract][Full Text] [Related]
12. Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia.
Jin W; Fei X; Wang X; Chen F; Song Y
J Immunol Res; 2020; 2020():5873056. PubMed ID: 32455140
[TBL] [Abstract][Full Text] [Related]
13. Analysis of circulating miRNAs 21 and 375 as potential biomarkers for early diagnosis of prostate cancer.
Gao Y; Guo Y; Wang Z; Dai Z; Xu Y; Zhang W; Liu Z; Li S
Neoplasma; 2016; 63(4):623-8. PubMed ID: 27268927
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
[TBL] [Abstract][Full Text] [Related]
15. A panel of five circulating microRNAs as potential biomarkers for prostate cancer.
Chen ZH; Zhang GL; Li HR; Luo JD; Li ZX; Chen GM; Yang J
Prostate; 2012 Sep; 72(13):1443-52. PubMed ID: 22298030
[TBL] [Abstract][Full Text] [Related]
16. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
17. A circulating miRNA assay as a first-line test for prostate cancer screening.
Sharova E; Grassi A; Marcer A; Ruggero K; Pinto F; Bassi P; Zanovello P; Zattoni F; D'Agostino DM; Iafrate M; Ciminale V
Br J Cancer; 2016 Jun; 114(12):1362-6. PubMed ID: 27228285
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Value of Peripheral Blood miR-374b-5p in Patients with Prostate Cancer.
Pang C; Song X; Fu C; Zhang Y; Zhang Y; Liu M
Clin Lab; 2020 Jan; 66(1):. PubMed ID: 32013356
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia.
Kiebish MA; Tekumalla P; Ravipaty S; Dobi A; Srivastava S; Wu W; Patil S; Friss T; Klotz A; Srinivasan A; Cullen J; Rosner IL; Ali A; Laszlo S; Petrovic M; Fleshner N; Garren J; Miller G; Mahaveer Chand N; Rodrigues LO; Granger E; Kellogg MD; Luan S; Diamandis E; Akmaev VR; Sarangarajan R; Bountra C; Freedland SJ; McLeod DG; Narain NR
Sci Rep; 2021 Jul; 11(1):15052. PubMed ID: 34302010
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of miR-148a-3p and miR-106a-5p as Biomarkers for Prostate Cancer: Pilot Study.
Coman RA; Schitcu VH; Budisan L; Raduly L; Braicu C; Petrut B; Coman I; Berindan-Neagoe I; Al Hajjar N
Genes (Basel); 2024 May; 15(5):. PubMed ID: 38790213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]